Abstract
The purpose of this prospective study was to compare the ability of radiolabelled somatostatin analogue (RSA) and metaiodobenzylguanidine (MIBG) scintigraphy to display carcinoid tumours. Forty patients were studied after radiological assessment based on clinical symptomatology. These patients had radiologically demonstrated tumours (n=28), resected tumours discovered to be of the carcinoid type (n=5) or clinically and biologically suspected carcinoid tumours (n=7). They underwent indium-111 DTPA-pentetreotide or iodine-123-Tyr-3-octreotide and131I-MIBG scintigraphy. The results were compared with those of complementary surgical or morphological examinations and analysed according to the site of the tumour and the symptomatology. In the case of 31 patients with a total of 55 tumoral sites, the sensitivity of the initial radiological assessment, of RSA and of MIBG was 96%, 86% and 64%, respectively, for the detection of at least one tumour per patient, but 51%, 85% and 51%, respectively, for the total number of sites. No site was detected solely by MIBG. The concordance between RSA and MIBG was better when all sites were considered (kappa index+0.44) than for only extrahepatic abdominal tumoral sites (kappa index+0.095). Abdominal, thoracic or bone marrow tumours were more easily detected with RSA than with MIBG. Hepatic invasion (21 cases) was more easily detected by radiology (sensitivity 100%) than by RSA and MIBG, both of which displayed a sensitivity of 80%, but with differences in uptake intensity. Tumour detection using MIBG was more significantly linked with flush (P<0.01) than with diarrhoea (P>0.10). In the assessment of carcinoid tumours, RSA scintigraphy should be carried out initially (just after hepatic ultrasonography) and supplemented by MIBG, as comparison of the studies serves to guide therapeutic options and might be valuable for prognosis.
Similar content being viewed by others
References
Pearse AGE, Polak JM, Heath CM. Polypeptide hormone production by “carcinoid” apudomas and their relevant cytochemistry.Virchows Arch B Cell Pathol 1974; 16: 95–109.
Erlandson RA. Tumors of the endocrine system: an overview.Ultrastruct Pathol 1994; 18: 149–170.
Limper AH, Carpenter PC, Scheithauser B, Staats BA. The Cushing's syndrome induced by bronchial carcinoid tumors.Ann Intern Med 1992; 117: 209–214.
Boissel P. Carcinoides. In: Proye C, Dubost C, eds.Endocrinologie Chirurgicale. Paris: Medsi/Macgraw-Hill; 1991: 217–241.
Hoefnagel CA, Taal BG, Valdes-Olmos RA. Role of [131I]metaiodobenzylguanidine therapy in carcinoids.J Nucl Biol Med 1991; 35: 346–348.
Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.Eur J Nucl Med 1994; 21: 561–581.
Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumours.Endocr Rev 1991: 12: 450–482.
Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, Bruns C, Joseph K, Arnold R. The role of Somatostatin analogs in the treatment of endocrine gastrointestinal tumours.Horm Metab Res Suppl 1993; 27: 24–27.
Smets LA, Bout B, Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodobenzylguanidine (MIBG).Cancer Chemother Pharmacol 1988; 21: 9–13.
Janson ET, Ronnblom L, Ahlstrom H, Grander D, Alm G, Einhorn S, Oberg K. Treatment with alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumours: a randomized trial.Ann Oncol 1992; 3: 635–638.
Zilembo N, Buzzoni R, Bajetta E, Di Bartolomeo M, de Brand F, Castellani R, Maffioli L, Celio L, Villa E, Lorusso V. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.Acta Oncol 1993; 32: 245–250.
Hoefnagel CA. Radionuclide therapy revisited.Eur J Nucl Med 1991; 18: 408–431.
Marsh HM, Martin JK, Kvols LK, et al. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue.Anesthesiology 1987; 66: 89–91.
Karmy-Jones R, Vallieres R. Carcinoid crisis after biopsy of a bronchial carcinoid.Ann thorac Surg 1993; 56: 292–295.
Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.Lancet 1989; I: 242–244.
Kvols LK, Reubi JC. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.Yale J Biol Med 1992; 65: 505–518.
Nocaudie-Calzada M, Huglo D, Deveaux M, Carnaille B, Proye C, Marchandise X. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.J Nucl Med 1994; 35: 57–62.
Phlipponneau M, Nocaudie M, Epelbaum J, de Keyzer Y, Lalau JD, Marchandise X, Bertagna X. Somatostatin analogs for the localisation and preoperative treatment of an adrenocorticotropin secreting bronchial carcinoid tumor.J Clin Endocrinol Metab 1994; 78: 20–24.
Nocaudie M, Huglo D, Deveaux M, Proye C, Marchandise X. Scintigraphie à l'Iode 123-Tyr-3-Octréotide et attitudes thérapeutiques. A propos de trois cas.Med Nucl 1993; 17: 74–80.
Bomanji J, Ur E, Mather S, Moyes J, Ellison D, Grossman A, Britton KE, Besser GM. A scintigraphic comparison of iodine-123-metaoiodobenzylguani dine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors. J Nucl Med 1992; 33: 1121–1124.
Reubi JC, Kvols LK, Waser B, Nagorney M, Heitz PU, Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinoma.Cancer Res 1990; 50: 5969–5977.
Krenning EP, Kwelckeboom DJ, Oei HY, de Jong RJB, Dop FJ, Reubi JC, Lamberts SWJ. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.Ann NY Acad Sci 1994; 733: 416–424.
Krenning EP, Kwekkeboom DJ, Bakker WH, Kooij PPM, Oei HY, van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with (111In-DTPA-d-Phe)-and (123I-Tyr-3)-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med 1993; 20: 716–731.
Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij P, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours.Eur J Nucl Med 1993; 20: 283–292.
Joseph K, Stapp J, Reinecke J, Skamel HJ, Höffken H, NeuhausC, Lenze H, Trautmann ME, Arnold R. Receptors scintigraphy with111In-pentetreotide for endocrine gastroenteropancreatic tumors.Horm Metab Res 1993; 27 Suppl: 28–35.
Slosman DO, Polla BS, Donath A.123I-MIBG pulmonary removal: a biochemical marker of minimal lung endothelial cell lesions.Eur J Nucl Med 1990; 16: 633–637.
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines with interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).Nucl Med Commun 1992; 13: 513–521.
Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.Eur J Nucl Med 1994; 21: 545–559.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nocaudie-Calzada, M., Huglo, D., Carnaille, B. et al. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 23, 1448–1454 (1996). https://doi.org/10.1007/BF01254466
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01254466